A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease.
The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions: How safe mirikizumab is and whether you might have any side effects when you t ...